Zestoretic

[Lisinopril/HCTZ]

Replacement Therapy

The combination may be substituted for the titrated individual components.

Use in Renal Impairment

Text Continues Below

---

Regimens of therapy with lisinopril/ HCTZ need not take account of renal function as long as the patient's creatinine clearance is >30 mL/ min/ 1.7m 2 (serum creatinine roughly <3 mg/ dL or 265 mmol/ L). In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so lisinopril/ HCTZ is not recommended (see WARNINGS, Anaphylactoid Reactions During Membrane Exposure).

HOW SUPPLIED

ZESTORETIC 10-12.5 Tablets (NDC 0310-0141) Peach, round, biconvex, uncoated tablets identified with "141" debossed on one side and "ZESTORETIC" on the other side are supplied in bottles of 100 tablets.

ZESTORETIC 20-12.5 Tablets (NDC 0310-0142) White, round, biconvex, uncoated tablets identified with "142" debossed on one side and "ZESTORETIC" on the other side are supplied in bottles of 100 tablets.

ZESTORETIC 20-25 Tablets (NDC 0310-0145) Peach, round, biconvex, uncoated tablets identified with "145" debossed on one side and "ZESTORETIC" on the other side are supplied in bottles of 100 tablets.

Store at controlled room temperature, 20-25° C (68-77° F) [see USP]. Protect from excessive light and humidity.

ZESTORETIC ® (Lisinopril and Hydrochlorothiazide)
Registered trademark of Hospal Ltd. All other trademarks are the property of the AstraZeneca group
© AstraZeneca 2002,2003

Manufactured for: AstraZeneca Pharmaceuticals LP
Wilmington, DE 19850 By: IPR Pharmaceuticals, Inc.
Carolina, PR 00984
Rev 05/ 03 PCC 660007
AstraZeneca

Page:  << Prev | 1 | 2 | 3